Avidity: 1st antibody oligonucleotide conjugate of Duchenne programs to enter clinic

 AOC 1044 is the first antibody oligonucleotide conjugate (AOC™) of multiple Duchenne muscular dystrophy programs to enter the clinic

First AOC from Avidity's RNA platform technology engineered to deliver phosphorodiamidate morpholino oligomers (PMO) to enter the clinic

Avidity has three distinct rare disease programs in clinical development

Volume 5 of virtual investor and analyst series on Thursday, October 13 at 10:00 am ET

The company is hosting Volume 5 of their virtual investor and analyst series on October 13, 2022, beginning at 10:00 a.m. ET to further discuss the AOC 1044 program. The event is a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event.

https://www.biospace.com/article/releases/avidity-biosciences-announces-phase-1-2-explore44-trial-of-aoc-1044-for-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping/